News

Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States

Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and metabolic diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UDP-003. UDP-003, designed by Cyclarity’s proprietary AI-enabled computational platform, is engineered to bind and extract oxidized cholesterol to restore cellular function and spur atherosclerotic plaque regression.

Latest news165

Four scientists standing in front of a glassed-off laboratory

First Drug Trial in US for Pill To Guard Against Nuclear Accidents

HOPO 14-1 is an investigative drug that is hoped can protect and treat victims of nuclear fallout, by binding (or chelating) contaminated heavy metals and removing them from the body. It is thought to be effective against Uranium and other materials used in nuclear weapons, such as dirty bombs or ballistic missiles. Read post
Katy Digovich

“Can I Cure My Diabetes With Stem Cells?” Katy Digovich Delivers TED Talk

CEO Katy Digovich recently gave a passionate TED Talk about her motivation for launching and leading Minutia. A former Princeton basketball player, Katy lives with diabetes. Working with the Clinton Global initiative in Africa, she learned that people with diabetes in the Third World face an early death sentence due to the cost of insulin monitoring and delivery. Minutia is developing cell therapy in the form of cells engineered with nanosensors to measure insulin levels and deliver dosage. Read post
Ray Therapeutics homepage with close-up of human face and eye

Ray Therapeutics: Anatomy Of A Biopharma VC Deal

Until 2010, leading a biotech wasn’t on Paul Bresge's radar. He’d built a long and successful career as a leader in unrelated industries -- industrial tools and a courier service, for example. Then, his 15-year-old daughter was diagnosed with retinitis pigmentosa, a rare genetic disease that causes degradation of retinal cells over time. She was going blind. Ophthalmologists told him there was nothing that could be done to save his daughter’s vision. Read post
View into the back of an ambulance responding to a call

Coagulant Therapeutics Announces Publication in Blood Advances Describing Novel Nanobody Library to Activated Protein C and Initial Leads for Treatment of Trauma and Hemophilia

By using assays specific for coagulation, inflammation and cell survival functions of APC, the investigators were able to identify an array of human APC specific antibodies able to retain or eliminate these functions. This represents a tool chest for APC targeted therapies that has already identified a lead candidate for the treatment of trauma and hemophilia. Read post
A large group of people on the steps of a building

Profluent Announces Launch With $9 Million Seed Round

Profluent is using deep generative models to ‘learn the language of biology’ in order to design new, functional proteins. The goal of protein design is to create novel or enhanced proteins with specific uses. These could include lasting cures for diseases that are free from patent restrictions or new enzymes that can break down unrecyclable plastics. Read post
Three burgers made with Black Sheep plant-based lamb

Black Sheep Foods Grabs $12.3M to Craft Tastier Plant-Based Meats

Venture capital into the food tech sector has been waning recently. However, by making flavors and also using them, Kumar believes Black Sheep Foods’ new funding is the result of setting the company up for a vertical integration approach that puts it in a unique space done only by Impossible Foods thus far. He adds the new round was planned and follows progress on some of the key things the company has set out to do in 2022, including the rate of product adoption and R&D milestones on its flavors. Read post
Katy Digovich at Bakar Labs

At Minutia, Katy Digovich Is Tackling Diabetes Cell by Cell

But while continuing to work in Africa with the Clinton Health Access Initiative, she learned she couldn't get far enough away. People were surprised when they learned that the nearly 6-foot-tall, athletic-looking Digovich — a former basketball player in college — was living with Type 1 diabetes, a diagnosis in Africa that often translates into stunted growth, amputation and high mortality. "Ultimately, I got really angry and the switch flipped. If I was born there, I would be dead. That really hit close to home," she said. "I took stock of my career and threw myself into the diabetes space." Read post
Valitor CEO Steven Lo (left) and President & CSO Wes Jackson (right)

Valitor Raises $28M Series B to Develop Therapy for Age-Related Macular Degeneration

The company will spend next year testing its multivalent polymer to prep for a clinical trial in 2024. The goal is to create an injectable that can last six months, meaning patients with wet AMD, a chronic eye condition that blurs vision and can sometimes cause blind spots, would only need two injections per year, kind of like going to the dentist, quipped Wesley Jackson, co-founder, president and CSO, in an interview with Endpoints News ahead of the launch. Read post